Cellebrite DI Ltd. $CLBT Shares Purchased by Nine Ten Capital Management LLC

Nine Ten Capital Management LLC increased its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 19.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,126,808 shares of the company’s stock after buying an additional 682,933 shares during the quarter. Cellebrite DI accounts for about 18.7% of Nine Ten Capital Management LLC’s investment portfolio, making the stock its 3rd largest position. Nine Ten Capital Management LLC’s holdings in Cellebrite DI were worth $60,251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also bought and sold shares of the company. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its holdings in shares of Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares during the period. Advisory Services Network LLC bought a new stake in shares of Cellebrite DI in the 3rd quarter worth about $40,000. CWM LLC increased its position in shares of Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after purchasing an additional 889 shares in the last quarter. Elevation Wealth Partners LLC acquired a new stake in shares of Cellebrite DI during the 2nd quarter worth about $44,000. Finally, Vestcor Inc bought a new position in Cellebrite DI during the 3rd quarter valued at about $70,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Insider Activity

In other Cellebrite DI news, CMO David Gee sold 4,323 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $11.36, for a total value of $49,109.28. Following the completion of the sale, the chief marketing officer directly owned 135,281 shares in the company, valued at $1,536,792.16. This represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CRO Marcus Jewell sold 12,562 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.24, for a total transaction of $141,196.88. Following the sale, the executive owned 427,128 shares in the company, valued at $4,800,918.72. This trade represents a 2.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 329,658 shares of company stock valued at $4,970,967. 5.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on CLBT shares. Needham & Company LLC reduced their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings lowered shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 27th. JPMorgan Chase & Co. cut their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Lake Street Capital reduced their target price on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, DA Davidson decreased their price target on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.70.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock opened at $11.45 on Wednesday. The firm has a fifty day moving average of $13.94 and a two-hundred day moving average of $13.64. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of 52.05, a PEG ratio of 1.76 and a beta of 1.15. Cellebrite DI Ltd. has a 52 week low of $9.58 and a 52 week high of $19.98.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.